The data to be presented includes safety and efficacy findings from the 0.25 mg and 0.50 mg dose cohorts of LP-310, administered once daily over four weeks in adults with symptomatic OLP. The primary ...

Alira Health, a global healthcare consulting and research organization, today released its fifth annual report on the state of the contract development and manufacturing organization (CDMO) market in ...

Gross profit for the first quarter of 2025 increased by $440 thousand, or 4.0%, to $11.4 million, compared with a gross profit of $10.9 million for the same quarter of 2024, as a result of higher ...